|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Trading: SELL @ $3.02
Signal Strength: WEAK
Indicator MUST BE USED in additional to another technical indicator to confirmation for trading entry. Indicator can be applied to the short term timeframe but is only able to give and indication of the strength of the buyers versus sellers at the market close. This bar analysis can provide guidance on the daily battle between sellers and buyers from the companies recent trading.
Opthea (ASX:OPT) buyers are becoming less eager.There has been 2 consecutive days of range decrease for OPT reducing strength to an uptrend in the first timeframe. The biggest price range this month has been $0.2900 & the greatest daily price range this year has been $0.2900. The price range ratio this week versus the quarterly price range is 1x & the price range ratio this month versus the year to date price range is 1x.
The range of the bar gives important information about the strength of weakness of a trend. If buyers are very committed they will be keen to buy and will tend to bid the price up even in the face of some selling pressure. Price will quickly & easily move upward and the move will tend to be significant. As such expanding ranges indicate the either buyers or sellers becoming more committed. Alternatively once the range begins to contract the side in control are losing commitment.
Calculation: Range Today Versus Range Yesterday (RTRY):
1) Expanding ranges on the upside indicates that buyers are increasingly eager;
2) Expanding ranges on the downside indicates that sellers are increasingly eager;
3) Contracting ranges on the upside indicates that buyers are becoming less eager;
4) Contracting ranges on the downside indicates that sellers are becoming less eager;
PROFILE: Opthea (OPT.AX)
Stock Exchange: ASX
Ticker Codes: | OPT.AX | ASX:OPT |
Opthea Limited develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase 1/2A clinical trial for the treatment of back of the eye diseases, such as wet age-related macular degeneration that is the cause of blindness in elderly and diabetic populations. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.
|MNS Milnes Holdings||0.19||35.7||7,820,143||0||BEARISH|
|FNP Freedom Nutritional Products||4.95||5.5||527,076||0||BEARISH|
|OCL Objective Corporation||6.1||5.2||45,754||0||BEARISH|
|CVW Clearview Wealth||0.51||5.2||34,015||-1||BEARISH|
|HVN Harvey Norman||4.42||4||4,591,659||-1||BEARISH|